The association between glucose-lowering drug use and mortality among breast cancer patients with type 2 diabetes

Breast Cancer Research and Treatment
Pauline A J VissersL J Murray

Abstract

This study assessed the association between glucose-lowering drug (GLD) use, including metformin, sulphonylurea derivatives and insulin, after breast cancer diagnosis and breast cancer-specific and all-cause mortality. 1763 breast cancer patients, diagnosed between 1998 and 2010, with type 2 diabetes were included. Cancer information was retrieved from English cancer registries, prescription data from the UK Clinical Practice Research Datalink and mortality data from the Office of National Statistics (up to January 2012). Time-varying Cox regression models were used to calculate HRs and 95 % CIs for the association between GLD use and breast cancer-specific and all-cause mortality. In 1057 patients with diabetes before breast cancer, there was some evidence that breast cancer-specific mortality decreased with each year of metformin use (adjusted HR 0.88; 95 % CI 0.75-1.04), with a strong association seen with over 2 years of use (adjusted HR 0.47; 95 % CI 0.26-0.82). Sulphonylurea derivative use for less than 2 years was associated with increased breast cancer-specific mortality (adjusted HR 1.70; 95 % CI 1.18-2.46), but longer use was not (adjusted HR 0.94; 95 % CI 0.54-1.66). In 706 patients who developed diabetes after breas...Continue Reading

References

Feb 3, 2005·The Lancet Oncology·Ido WolfBella Kaufman
Jun 15, 2005·European Journal of Cancer Care·R McCoubrieL Dawes
Oct 26, 2006·Cancer Research·Mahvash ZakikhaniMichael Pollak
Jan 19, 2007·International Journal of Cancer. Journal International Du Cancer·Lonneke V van de Poll-FranseHarm R Haak
Jun 3, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sao JiralerspongAna M Gonzalez-Angulo
Jan 7, 2010·BMC Family Practice·Nada F KhanPeter W Rose
Dec 1, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kimberly S PeairsAntonio C Wolff
Dec 2, 2010·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Jaclyn Lee Fong BoscoTimothy L Lash
May 6, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Guilherme Z RochaJosé B C Carvalheira
Nov 25, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·X HeS-C J Yeung
Nov 29, 2011·Clinical Science·Benoit ViolletFabrizio Andreelli
Jun 13, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Rowan T ChlebowskiDavid M Euhus
Aug 1, 2012·International Journal of Cancer. Journal International Du Cancer·Catherine DugganAnne McTiernan
Aug 1, 2012·Breast Cancer Research and Treatment·Nananda F ColRowan T Chlebowski
Nov 23, 2012·Diabetes Care·Samy Suissa, Laurent Azoulay
Aug 14, 2013·Journal of the National Cancer Institute·Jessica ChubakNoel S Weiss
Jun 20, 2014·Cancer Medicine·Bridget A OppongTari A King
Jul 26, 2014·PloS One·Suren SarkissyanJaydutt V Vadgama

❮ Previous
Next ❯

Citations

Mar 15, 2016·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Úna C Mc MenaminLiam M Murray
Jan 1, 2016·Cell Death & Disease·Y Poloz, V Stambolic
Jun 21, 2015·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·L Van De VoordeP Lambin
Aug 4, 2015·Journal of Endocrinological Investigation·F CoperchiniL Chiovato
Apr 14, 2016·Reviews in Endocrine & Metabolic Disorders·Jana EngelmannUlrike Rothe
Jul 15, 2015·Oxidative Medicine and Cellular Longevity·Patrizia FerroniMario Roselli
May 11, 2016·Pharmaceuticals·Panagiota PapanagnouMaria Tsironi
May 18, 2016·Diabetes/metabolism Research and Reviews·Lan MuXin Wang
Nov 3, 2016·Nature Reviews. Clinical Oncology·Adi J Klil-DroriMichael N Pollak
Dec 23, 2017·Biological Chemistry·Stephen SafeKeshav Karki
Apr 23, 2019·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·J RahmaniY Zhang
Jul 28, 2017·Expert Opinion on Drug Safety·Marco TuccoriCorrado Blandizzi
May 23, 2018·Journal of the National Cancer Institute·Ruth E PattersonLoki Natarajan
Apr 6, 2018·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Grace H TangPaola Muti
Sep 19, 2021·Cancer Cell International·Ahmed OlatundeJavad Sharifi-Rad

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.